Roche Covid-19 Antibody Trial Meets Primary Endpoint
By Cecilia Butini
Roche Holding AG said Tuesday that a phase-3 clinical trial
assessing an antibody cocktail to treat Covid-19 in
non-hospitalized patients met its primary endpoint.
The Swiss pharma major said its investigational antibody
cocktail of casirivimab and imdevimab reduced the risk of
hospitalization or death by 70% compared with a placebo.
The drugs also met the secondary endpoints of the study, which
included the ability to reduce symptom duration from 14 to 10 days,
the company said.
It added that it would soon share results from the trial with
regulatory authorities and from another phase 2/3 study on the use
of the same drugs in hospitalized patients.
On Feb 26, the European Medicines Agency's Committee for
Medicinal Products for Human Use issued a positive opinion
supporting use of the cocktail for the treatment of Covid-19
Write to Cecilia Butini at firstname.lastname@example.org
(END) Dow Jones Newswires
March 23, 2021 02:35 ET (06:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.